ClinicalTrials.govpublic full text
Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial
triple negative breast cancer, tucidinostat, capecitabine, metronomic therapy, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 872241
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.